Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRX 195183 and Arsenic Trioxide in Untreated APL
NCT00670150Phase 2Withdrawn
- Sponsor
- University of Southern California
- Start
- May 2010
- Primary completion
- Aug 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irx-5183 in acute promyelocytic leukemia (APL), sponsored by University of Southern California. Primary endpoint: Partial or Complete Response Rate. Planned start May 2010; status: withdrawn.
02
Drugs
irx-5183
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00670150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00670150.